BEST-CLI International Collaborative: planning a better future for patients with chronic limb-threatening ischaemia globally.

The article discusses the BEST-CLI International Collaborative, which aims to improve care and outcomes for patients with chronic limb-threatening ischemia (CLTI) globally. The article highlights the increasing prevalence of peripheral arterial disease (PAD) and the need for evidence-based treatment strategies for CLTI. The BEST-CLI trial, funded by the National Heart, Lung, and Blood Institute, compared open surgery and endovascular therapy for CLTI patients. The article also mentions the BASIL-2 trial, which compared different revascularization strategies for CLTI. The BEST-CLI International Collaborative seeks to interpret the trial results, identify gaps in CLTI care, disseminate evidence-based medicine, and identify future research priorities. The text discusses the findings of a survey conducted among vascular specialists from 22 countries regarding the treatment of chronic limb-threatening ischemia (CLTI). The survey revealed wide disparities in the management of CLTI, including variations in patient demographics, diagnostic classification, treatment approaches, and costs. The text emphasizes the need for global education and collaboration to promote best practices in CLTI treatment and ensure equal access to evidence-based care. It also highlights the importance of considering local contexts and health economics when implementing treatment strategies. Additionally, the text mentions the potential of new technologies to improve revascularization outcomes and the importance of training programs to enhance physician skills in CLTI interventions. The text discusses the evolution of new technology in caring for patients with critical limb-threatening ischemia (CLTI) and emphasizes the importance [Extracted from the article]